51.6±5.4% decay-corrected yield (n=6, 1.1-2.9 GBq at the end of synthesis). The total duration of the synthesis was 2 hours. Radiochemical purity was ˃99% and the specific activity varied between 12-809 GBq/µmol at EOS.
Preparation of TCO-nanoparticles
The porous silicon nanoparticles were prepared by electrochemically anodizing p+ type Si (100) wafers of 0.01-0.02 Ωcm resistivity in a 1:1 (vol.) hydrofluoric acid (38%) -ethanol electrolyte. A pulsed etching profile was used to produce PSi multilayer films with alternating low and high porosity regions to facilitate the production of the nanoparticles. The multilayer films were thermally hydrocarbonized with acetylene as described earlier. 2 The treated films were then immersed into undecylenic acid for 16 h at 120 °C for partial COOH termination. The films were ball milled in 10 vol-% undecylenic acid-decane solution into nanoparticles. The final size selection was done using centrifugation.
The -COOH terminated PSi NPs (UnTHCPSi) were functionalized by activating the carboxylic acid groups with EDC/NHS cross-linking chemistry carbodiimide/N-hydroxysuccinimide) by dispersing the NPs in 5 mM EDC/NHS-ethanol solution for 1 h. The activated NPs were then dispersed into 100 mM 3-azidopropylamine-chloroform solution to generate an azide terminated surface.
The N 3 -PSi NPs were then dispersed into 3.33 mM trans-cyclooctene-PEG 12 -dibenzocyclooctyne (TCO-PEG 12 -DBCO)-chloroform solution for a strain-promoted azide-alkyne cycloaddition for 4 h.
The excess reagents were washed from the particles using chloroform and ethanol.
Characterization of TCO-nanoparticles
Structural characteristics of the PSi NPs were determined with nitrogen sorption at -196 °C using a Micromeritics TriStar 3000. The specific surface area of the NPs was calculated using the Brunauer-Emmett-Teller theory and the total pore volume by taking the total adsorbed amount of N 2 at relative pressure p/p 0 = 0.97. The average pore diameter was calculated as d=4V/A assuming SI 3 the pore shape as cylindrical. The obtained surface area of the NPs was 242 ± 4 m 2 /g and the total pore volume 0.71 ± 0.01 cm 3 /g. The calculated average pore diameter was 11.8 ± 0.4 nm.
The hydrodynamic diameter (Z-average) and the particle zeta potential were determined with dynamic and electrophoretic light scattering, respectively, using Malvern Zetasizer Nano ZS. The Z-average and the polydispersity index (PdI) of the particles at different stages of modification are listed in Table S1 . Figure S1 . Initially, the -COOH terminated particles show a broad band centered around 1715 cm -1 , related to the carbonyl stretch vibration of the carboxylic acid group. After activation, a triplet of peaks is observable at slightly higher wavenumbers at 1745, 1790, and 1820 cm -1 , that can be ascribed to the formation of succinimidyl terminated groups.
Conjugating the azidopropylamine to the NPs causes the triplet peaks to disappear, while broad bands around 1650 and 1545 cm -1 are formed, confirming its amide bonding. Also, a strong peak is visible at 2100 cm -1 due to the azide stretching vibrations.
Elemental analysis was performed to determine the amount of conjugated TCO. The calculation was based on the increase of nitrogen between azide step and final product. The following formula was used:
where %N mass of nitrogen, and number 3 is used because TCO-PEG12-DBCO moiety has three nitrogen atoms.
The elemental analysis results were 0.64% and 0.67% of nitrogen for azide step and final product, respectively. Using the above formula results 0.0071 mmol/g. Each animal in the group that received nanoparticles received a dose of 0.2 mg of TCO-NPs (1.42 nmol of TCO).
SI 5 FIGURE S1. Photoacoustic FTIR spectra of the PSi NPs at different stages of the surface modification. (i) UnTHCPSi, (ii) succinimidyl-terminated THCPSi, (iii) N 3 -terminated THCPSi and (iv) TCO-PEG 12 -DBCO modified THCPSi.
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In vitro reactivity of TCO-NPs 
Animal experiments
All animal experiments were performed according to the respective national and European legislation with an approved ethical license from the National Board on Animal Experimentation [ 18 F]1 was administered at a dose of 6.2 ± 2.5 MBq in 50-100 µl 10% EtOH 0.9 % NaCl followed by a flush of the catheter with 50 µl of 0.9% NaCl. The animals were sacrificed under anesthesia by cervical dislocation at designated time points after tracer administration and samples of tissues and body fluids were collected for radioactivity measurements. Tissue samples were counted on an automated gamma counter (Wizard 3, PerkinElmer, Turku, Finland) for 60 s with three repeats for each sample.
For PET imaging studies with TCO-NPs, isoflurane/oxygen inhalation anesthetics (0.5 l/min O 2 , 2% isoflurane) was applied. Prior to imaging the jugular vein of the mouse was cannulated for i.v.
administration of the tracer. The mouse was positioned in the Mediso nanoScan® PET-CT (Mediso, Budapest, Hungary) and prior to injection of the tracer, a routine CT Helican scan was made.
Thereafter, the tracer (5.2±0.6 MBq, specific activity 302-809 GBq/µmol at EOS) was injected and PET acquisition was performed for 60 min (Mediso Nucline acquisition software). Reconstruction software provided by Mediso (3D Tera-Tomo reconstruction method using OSEM) was applied according to the manufacturer's instructions, including corrections for decay, randoms, dead time, and attenuation. The bed was manually removed from the PET-CT image. ROI normalized with the injected radioactivity dose and animal weight, and as time-activity curve (TAC). After PET/CT imaging, mice were sacrificed, various tissues were excised, weighed and measured for radioactivity by using a gamma counter (3 NaI, Triathler 425-010, Hidex, Turku, Finland). The radioactivity measurements were corrected for the radionuclide decay to the time of injection, ex vivo biodistribution results were expressed as percentage of injected radioactivity dose per gram of tissue (%ID/g). The particles were dissolved in 5.4% glucose solution, and again centrifuged (10 000 g, 5 min) and the pellet and supernatant were measured with dose calibrator. The particles were dissolved in 5.4%
glucose solution by using Vortex and injected to animals. Based on these results the concentration of TCO-NPs in spleen in pretargeted experiments were evaluated. The %ID/g values were used to calculate how many milligrams of TCO-NPs (total injected amount was 0.2 mg) should be found from the spleen. Kinetic modeling FIGURE S7. Tissue to blood curves.
